Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recovery and Survival of INTERCEPT Treated Platelets
NCT02310412Phase 2Completed
- Sponsor
- Cerus Corporation
- Start
- Dec 2014
- Primary completion
- May 2015
- Modality
- Cell Therapies
01
Overview
Phase 2, open-label trial of INTERCEPT Platelets in Thrombocytopenia (2 arms), sponsored by Cerus Corporation. Primary endpoints: Post infusion recovery ratio of Test platelets at Day 7 compared to fresh platelets, Post infusion lifespan ratio of Test platelets at Day 7 compared to fresh platelets and 2 more. Started Dec 2014; status: completed.
02
Drugs
INTERCEPT Platelets
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT02310412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02310412.